As a core component of the adaptive immune system, T cells originate from hematopoietic stem cells in the bone marrow, followed by migration to the thymus for differentiation and maturation. Along this sophisticated differentiation pathway, CD4+ T cells—a critical subset—initiate their functional specialization upon receiving dual-signal stimulation from antigen-presenting cells (APCs). The first signal arises from the recognition of antigenic peptides presented by major histocompatibility complex class II molecules (MHC II) via the T cell receptor (TCR). The second signal is mediated by the interaction of co-stimulatory molecules (e.g., CD28 and B7).
Naive CD4+ T cells (Th0 cells), upon stimulation by specific antigens, can differentiate into distinct helper T cell subsets under the guidance of a specific cytokine microenvironment. Among these subsets, Th1 cell differentiation is primarily driven by interferon-gamma (IFN-γ) and interleukin-12 (IL-12). IFN-γ activates the STAT1 signal transduction pathway, while IL-12 acts through the STAT4 pathway; together, these two pathways induce the expression of the T-bet transcription factor. As the master regulator of Th1 cell differentiation, T-bet not only promotes the sustained production of IFN-γ but also inhibits the expression of transcription factors specific to other Th subsets, thereby establishing the stable phenotype of Th1 cells.
The full activation of Th1 cells relies on a complex intracellular signaling network. Following the recognition of the antigen-MHC II complex by the TCR, the downstream ZAP-70 kinase is activated, which in turn initiates multiple signaling cascades, including the calcineurin-NFAT pathway, protein kinase C-NF-κB pathway, and RAS-MAPK pathway. The synergistic action of these pathways drives the production of autocrine growth factors (e.g., IL-2), enabling T cell clonal expansion.
In terms of cytokine signaling, after IL-12 binds to its receptor, it activates STAT4 via JAK2 and TYK2 kinases; in contrast, IFN-γ activates STAT1 through JAK1 and JAK2. These activated STAT proteins form homo- or heterodimers, translocate into the nucleus, and bind to the promoter region of the T-bet gene, further consolidating the differentiated state of Th1 cells. Additionally, the CD40-CD40L interaction provides a crucial co-stimulatory signal between Th1 cells and APCs, enhancing cytokine production and immune function.
Th1 cells coordinate immune responses primarily through the secretion of specific cytokines and the expression of surface molecules. Among these, IFN-γ is the most characteristic effector molecule of Th1 cells: it activates the antibacterial functions of macrophages, upregulates MHC molecule expression, and promotes the differentiation of Th1 cells themselves, forming a positive feedback loop. Meanwhile, cytokines of the tumor necrosis factor (TNF) family play a key role in controlling intracellular pathogen infections by inducing inflammatory responses and promoting cell apoptosis.
In the recruitment and activation of innate immune cells, IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by Th1 cells promote the production and release of monocytes from the bone marrow. Subsequently, through the production of chemokines and cytokines, Th1 cells guide these innate immune cells to migrate to sites of infection or inflammation. Notably, the binding of CD40L (expressed on Th1 cells) to CD40 on the macrophage surface significantly enhances the phagocytic and bactericidal activities of macrophages, establishing an effective link between adaptive and innate immunity.
The central role of Th1 cells in immune responses is reflected in their dual regulation of cellular and humoral immunity. By secreting IL-2, Th1 cells not only promote their own proliferation but also activate the differentiation and function of CD8+ cytotoxic T lymphocytes (CTLs), enhancing the clearance of virus-infected cells and tumor cells. This Th1-CTL axis is crucial for controlling intracellular pathogens and mediating tumor immune surveillance.
In the regulation of humoral immunity, Th1 cells modulate B cell class switching via IFN-γ, promoting the production of immunoglobulin G (IgG)—particularly the IgG2a subclass (IgG1 in humans), which exhibits potent complement activation and opsonophagocytic capabilities. This specific antibody response is of great significance for the clearance of extracellular bacteria and viruses. Furthermore, through direct cell-cell contact and cytokine secretion, Th1 cells assist B cells in completing affinity maturation in germinal centers, leading to the production of high-affinity antibodies.
The accurate identification of Th1 cells depends on their unique surface markers and intracellular cytokine expression profiles. Traditionally, flow cytometry is used to preliminarily identify Th1 cells by detecting the expression of CD3, CD4, and CXCR3. As a chemokine receptor characteristic of Th1 cells, CXCR3 guides cell migration to inflammatory sites, and its ligands include IFN-γ-inducible chemokines (CXCL9, CXCL10, and CXCL11).
At the transcriptional level, T-bet (encoded by the TBX21 gene) is recognized as the master regulator of Th1 cell differentiation. It maintains the stable phenotype of Th1 cells by directly activating IFNG gene transcription and inhibiting the expression of genes specific to other Th subsets. With the advancement of single-cell RNA sequencing technology, researchers can now simultaneously analyze the expression of multiple marker genes (including CD3D, CD3E, CD3G, CD4, CXCR3, TBX21, and IFNG), enabling more precise distinction of Th1 cells and their functional states. This multiparametric analysis approach has also revealed heterogeneity within Th1 cells, including the presence of effector, memory, and circulating subsets.
Th1 cells and their secreted cytokines exhibit complex dual roles in diseases. In anti-infective immunity, Th1 responses are essential for controlling intracellular pathogens (e.g., Mycobacterium tuberculosis, Leishmania spp., and viruses). Appropriate Th1 activity effectively clears pathogens; however, excessive or persistent activation may lead to tissue damage and chronic inflammation. Dysregulation of this balance is particularly prominent in various autoimmune diseases.
In the field of organ transplantation, Th1 cells promote immune rejection of grafts by activating macrophages and CTLs. Studies have shown that the levels of Th1 cells and related cytokines in the peripheral tissues and blood of patients with acute rejection are significantly elevated. In contrast, Th1 responses are suppressed in patients with established transplant tolerance. Similar mechanisms are observed in autoimmune diseases such as multiple sclerosis, type 1 diabetes, and rheumatoid arthritis, where Th1 cell-mediated inflammatory responses cause damage to specific target tissues.
In tumor immunity, Th1 cells exert a protective role. A high abundance of Th1 cells in the tumor microenvironment is associated with favorable clinical outcomes, as the cellular immune responses they activate can effectively recognize and eliminate tumor cells. Th1 cells directly inhibit tumor cell proliferation by secreting IFN-γ, activate the tumor-killing function of macrophages, and promote the infiltration and activity of CTLs. Therefore, enhancing Th1 responses has become a key strategy in cancer immunotherapy.
With advancements in single-cell technology and epigenetic analysis methods, Th1 cell research has entered a new phase. Future studies will focus on dissecting the heterogeneity of Th1 cells in different tissue microenvironments, clarifying their interaction networks with other immune cells (e.g., Tregs, Th17 cells), and exploring the regulatory role of metabolic reprogramming in Th1 cell function.
In terms of therapeutic applications, strategies to modulate Th1 responses show broad prospects. In autoimmune diseases and transplant rejection, drugs that specifically inhibit Th1 cell differentiation and function (e.g., antibodies targeting the IL-12/IL-23 pathway) have demonstrated clinical efficacy. Conversely, in tumors and chronic infections, enhancing Th1 responses through vaccine adjuvants, cytokine therapy, or immune checkpoint inhibitors may improve disease control. Of particular interest are epigenetic regulation and metabolic intervention strategies based on T-bet, which may provide new therapeutic avenues for the precise modulation of Th1 cell function.
Understanding Th1 cell biology not only helps unravel the fundamental principles of immune regulation but also provides novel targets and insights for the immunotherapy of various diseases. As research progresses, Th1 cells continue to demonstrate their central role in maintaining immune homeostasis and coordinating defensive responses, laying a solid foundation for the development of precise immune intervention strategies in the future.
Business license (three certificates in one) 